Mesothelioma Research | Targeted Therapy | Mesothelioma Treatment

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA. suresh.ramalingam@emory.edu


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376